Abstract
Imiquimod, the lead compound of the imidazoquinoline family of nucleoside analogues, has shown good efficacy against a variety of tumors of different origin. The mode of action of imiquimod and related compounds, which we have begun to understand in some detail in recent years, is complex and interesting inasmuch as it appears to comprise several presumably mutually enhancing components. Predominant amongst its actions is the induction of pro-inflammatory cytokines through agonistic activity towards Tolllike receptor (TLR)-7 and TLR-8, and consecutively, activation of the central transcription factor NF- κB. This activity stimulates the production of pro-inflammatory cytokines, chemokines and other mediators resulting in activation of antigen- presenting cells and the mounting of a profound Th1-weighted antitumoral cellular immune response. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of NF-κB. The pro-inflammatory activity of imiquimod appears to be augmented by suppression of a negative regulatory feedback mechanism which normally limits inflammatory responses. This is achieved independent of TLR-7 and TLR-8 through interference with adenosine receptor signaling pathways, particularly the A2A subtype, and receptor-independent reduction of adenylyl cyclase activity. Finally, at higher, albeit therapeutically relevant concentrations, imiquimod exerts a pro-apoptotic activitiy against tumor cells. Induction of apoptosis by imiquimod appears to be dependent on Bcl-2 proteins and involves caspase activation. The combination of multiple, presumably synergistic anti-tumoral functions by a single compound represents an interesting principle of pathogenesis-oriented, anti-neoplastic therapy.
Keywords: inflammatory cytokines, transcription, Toll like receptors, immune response, Pro-Apoptotic
Current Medicinal Chemistry
Title: The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Volume: 14 Issue: 6
Author(s): Margarete Schon and Michael P. Schon
Affiliation:
Keywords: inflammatory cytokines, transcription, Toll like receptors, immune response, Pro-Apoptotic
Abstract: Imiquimod, the lead compound of the imidazoquinoline family of nucleoside analogues, has shown good efficacy against a variety of tumors of different origin. The mode of action of imiquimod and related compounds, which we have begun to understand in some detail in recent years, is complex and interesting inasmuch as it appears to comprise several presumably mutually enhancing components. Predominant amongst its actions is the induction of pro-inflammatory cytokines through agonistic activity towards Tolllike receptor (TLR)-7 and TLR-8, and consecutively, activation of the central transcription factor NF- κB. This activity stimulates the production of pro-inflammatory cytokines, chemokines and other mediators resulting in activation of antigen- presenting cells and the mounting of a profound Th1-weighted antitumoral cellular immune response. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of NF-κB. The pro-inflammatory activity of imiquimod appears to be augmented by suppression of a negative regulatory feedback mechanism which normally limits inflammatory responses. This is achieved independent of TLR-7 and TLR-8 through interference with adenosine receptor signaling pathways, particularly the A2A subtype, and receptor-independent reduction of adenylyl cyclase activity. Finally, at higher, albeit therapeutically relevant concentrations, imiquimod exerts a pro-apoptotic activitiy against tumor cells. Induction of apoptosis by imiquimod appears to be dependent on Bcl-2 proteins and involves caspase activation. The combination of multiple, presumably synergistic anti-tumoral functions by a single compound represents an interesting principle of pathogenesis-oriented, anti-neoplastic therapy.
Export Options
About this article
Cite this article as:
Schon Margarete and Schon P. Michael, The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines, Current Medicinal Chemistry 2007; 14 (6) . https://dx.doi.org/10.2174/092986707780059625
DOI https://dx.doi.org/10.2174/092986707780059625 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Targeting of the Inflamed Intestinal Barrier
Current Pharmaceutical Design Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Investigation of the Antiproliferative Action of the Quinoline Alkaloids Kokusaginine and Skimmianine on Human Cell Lines
Current Signal Transduction Therapy Potential Role of miRNA in Metastatic Cascade of Triple-Negative Breast Cancer
Current Cancer Drug Targets ABC Pumps and Their Role in Active Drug Transport
Current Topics in Medicinal Chemistry The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) New Avenue of Research: Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
Recent Patents on CNS Drug Discovery (Discontinued) Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry The Role of the Calcium-Sensing Receptor in Bone Biology and Pathophysiology
Current Pharmaceutical Biotechnology Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?
Current Gene Therapy Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
Current Genomics Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Osteoblast Differentiation and Control by Vitamin D and Vitamin D Metabolites
Current Pharmaceutical Design